Dragonfly Biosciences, the UK-based maker of cannabidiol-based supplements and lotions, is locked-and-loaded for an initial public offering and ASX listing next month.
Dragofly, which is led by Regan Saveall, intends to raise up to $5 million at 20¢ a share, valuing the business at between $37 million and $40 million. Financing is jointly led by Finexia Securities and RM Corporate Finance.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
